Skip to main content
    J

    Johnson & Johnson (JNJ)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $282.84
    -2.91 (-1.02%)

    Market Cap: $687.89B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Johnson & Johnson (JNJ) Earnings: Report Dates and Results

    Updated Oct 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Johnson & Johnson (JNJ) is confirmed to report earnings on Jan 26, 2027, after the close. In the quarter ended Sep 30, 2026, Johnson & Johnson reported EPS of $2.59, above the $2.53 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    98%(39/40)
    Avg Surprise
    +4.28%
    Streak
    3 Q

    Upcoming Estimates

    Reports Jan 26, 2027 after closePeriod ending Dec 31, 2026
    EPS Consensus$2.94
    Range$2.80 - $3.10
    18 analysts
    Revenue Consensus
    $26.69B
    Range$25.70B - $28.02B
    17 analysts
    Reports Apr 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.67
    Range$2.57 - $2.87
    7 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$2.78-3.6%
    60d ago$2.78-3.6%
    30d ago$2.80-4.6%
    7d ago$2.68-0.1%
    Current$2.67
    Revenue Consensus
    $25.55B
    Range$25.30B - $26.20B
    6 analysts

    Next Report

    JNJ has a confirmed report date of Jan 26, 2027, after the close. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.5% above the $2.46 reported for the quarter ended Dec 31, 2025.

    JNJ Earnings Call

    The latest JNJ earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, JNJ beat 39 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $25.40B, up 5.9% from $23.99B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.59$2.53$2.31 - $2.81+2.37%Beat-7.5%130 up, 0 downOct 13, 2026$25.40B
    Jun 30, 2026$2.90$2.84$2.65 - $3.00+2.11%Beat+4.7%170 up, 2 downJul 15, 2026$25.31B
    Mar 31, 2026$2.70$2.68$2.14 - $2.89+0.75%Beat-2.5%182 up, 4 downApr 14, 2026$24.06B
    Dec 31, 2025$2.46$2.46$2.37 - $2.570.00%In line+20.6%200 up, 12 downJan 21, 2026$24.56B
    Sep 30, 2025$2.80$2.76$2.65 - $2.84+1.45%Beat+15.7%193 up, 2 downOct 14, 2025$23.99B
    Jun 30, 2025$2.77$2.68$2.56 - $2.99+3.36%Beat-1.8%18N/AJul 16, 2025$23.74B
    Mar 31, 2025$2.77$2.58$2.40 - $2.84+7.36%Beat+2.2%171 up, 7 downApr 15, 2025$21.89B
    Dec 31, 2024$2.04$2.01$1.90 - $2.36+1.49%Beat-10.9%193 up, 2 downJan 22, 2025$22.52B
    Sep 30, 2024$2.42$2.21$1.99 - $2.42+9.50%Beat-9.0%145 up, 1 downOct 15, 2024$22.47B
    Jun 30, 2024$2.82$2.70$2.61 - $2.75+4.44%Beat+0.7%153 up, 0 downJul 17, 2024$22.45B
    Mar 31, 2024$2.71$2.65$2.56 - $2.74+2.26%Beat+1.1%154 up, 1 downApr 16, 2024$21.38B
    Dec 31, 2023$2.29$2.28$2.25 - $2.31+0.44%Beat-2.6%152 up, 1 downJan 23, 2024$21.39B
    Sep 30, 2023$2.66$2.52N/A+5.56%Beat+4.3%154 up, 1 downOct 17, 2023$21.35B
    Jun 30, 2023$2.80$2.62$2.54 - $2.69+6.87%Beat+8.1%172 up, 1 downJul 20, 2023$21.52B
    Mar 31, 2023$2.68$2.50$2.34 - $2.59+7.20%Beat+0.4%162 up, 1 downApr 18, 2023$20.89B
    Dec 31, 2022$2.35$2.24$2.19 - $2.26+4.91%Beat+10.3%142 up, 1 downJan 24, 2023$12.55B
    Sep 30, 2022$2.55$2.49$2.21 - $2.64+2.41%Beat-1.9%141 up, 1 downOct 18, 2022$20.00B
    Jun 30, 2022$2.59$2.55$2.41 - $2.70+1.57%Beat+4.4%140 up, 0 downJul 19, 2022$24.02B
    Mar 31, 2022$2.67$2.57$2.16 - $2.77+3.89%Beat+3.1%142 up, 4 downApr 19, 2022$23.43B
    Dec 31, 2021$2.13$2.12$2.01 - $2.15+0.47%Beat+14.5%140 up, 0 downJan 25, 2022$9.77B
    Sep 30, 2021$2.60$2.35$2.23 - $2.52+10.64%Beat+18.2%14N/AOct 19, 2021$23.34B
    Jun 30, 2021$2.48$2.28$2.17 - $2.43+8.77%Beat+48.5%12N/AJul 21, 2021$23.31B
    Mar 31, 2021$2.59$2.35$2.20 - $2.59+10.21%Beat+12.6%15N/AApr 20, 2021$22.32B
    Dec 31, 2020$1.86$1.83$1.76 - $1.89+1.64%Beat-1.1%15N/AJan 26, 2021$22.48B
    Sep 30, 2020$2.20$1.98$1.79 - $2.13+11.11%Beat+3.8%15N/AOct 13, 2020$21.08B
    Jun 30, 2020$1.67$1.51$1.33 - $1.69+10.60%Beat-35.3%16N/AJul 16, 2020$18.34B
    Mar 31, 2020$2.30$2.00$1.75 - $2.19+15.00%Beat+9.5%13N/AApr 14, 2020$20.69B
    Dec 31, 2019$1.88$1.87$1.82 - $1.94+0.53%Beat-4.6%15N/AJan 22, 2020$20.75B
    Sep 30, 2019$2.12$2.01$1.97 - $2.06+5.47%Beat+3.4%16N/AOct 15, 2019$20.73B
    Jun 30, 2019$2.58$2.44$2.30 - $2.66+5.74%Beat+22.9%17N/AJul 16, 2019$20.56B
    Mar 31, 2019$2.10$2.04$1.95 - $2.17+2.94%Beat+1.9%16N/AApr 16, 2019$20.02B
    Dec 31, 2018$1.97$1.95$1.93 - $1.97+1.03%Beat+13.2%16N/AJan 22, 2019$20.39B
    Sep 30, 2018$2.05$2.03$1.97 - $2.07+0.99%Beat+7.9%16N/AOct 16, 2018$20.35B
    Jun 30, 2018$2.10$2.07$2.03 - $2.25+1.45%Beat+14.8%18N/AJul 17, 2018$20.83B
    Mar 31, 2018$2.06$2.00$1.76 - $2.19+3.00%Beat+12.6%18N/AApr 17, 2018$20.01B
    Dec 31, 2017$1.74$1.72$1.69 - $1.75+1.16%Beat+10.1%19N/AJan 23, 2018$20.20B
    Sep 30, 2017$1.90$1.80$1.73 - $1.85+5.56%Beat+13.1%20N/AOct 17, 2017$19.65B
    Jun 30, 2017$1.83$1.79$1.74 - $1.86+2.23%Beat+5.2%18N/AJul 18, 2017$18.84B
    Mar 31, 2017$1.83$1.77N/A+3.39%Beat+8.9%N/AN/AApr 18, 2017$17.77B
    Dec 31, 2016$1.58$1.56N/A+1.28%Beat+9.7%N/AN/AJan 24, 2017$18.11B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $10.80, up 8.1% from the year before. It was $6.68 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$10.80+8.1%
    Dec 31, 2024$9.99-4.2%
    Dec 31, 2023$10.43+2.7%
    Dec 31, 2022$10.16+3.7%
    Dec 31, 2021$9.80+22.0%
    Dec 31, 2020$8.03-7.5%
    Dec 31, 2019$8.68+6.1%
    Dec 31, 2018$8.18+12.1%
    Dec 31, 2017$7.30+9.3%
    Dec 31, 2016$6.68N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,22916
    2026Q2Jun 30, 20269,20916
    2026Q1Mar 31, 20268,90616
    2025Q4Dec 31, 202510,85216
    2025Q3Sep 30, 202511,07718
    2025Q2Jun 30, 20252,7588
    2025Q1Mar 31, 20258,17416
    2024Q4Dec 31, 20249,74615

    2026Q3 Earnings Call

    Opening remarks

    Ryan Koors Vice President, Investor Relations Hello, everyone. This is Ryan Koors, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the third quarter of 2026 and our financial outlook for the full year. First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording. They are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. The description of these risks, uncertainties, and other factors can be found in our SEC filings, including our 2025 Form 10-K, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. Moving to today's agenda, Joaquin Duato, our Chairman and CEO, will discuss our business performance and growth drivers. I will then review the third-quarter sales and P&L results. Joe Wolk, our CFO, will then close by sharing an overview of our capital allocation priorities and updated guidance for 2026. Tom Cavanagh, Executive Vice President, Worldwide Chairman, Innovative Medicine; John Reed, Executive Vice President, Innovative Medicine Research and Development; and Timothy Schmid, Executive Vice President, Worldwide Chairman, MedTech, will be joining us for Q&A. To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes. With that, I will now turn the call over to Joaquin.

    Joaquin Duato Chairman and CEO Thank you, Ryan, and good morning, everyone. Our strong performance in the third quarter reinforces our confidence in 2026 as a year of accelerated growth and impact for Johnson & Johnson. In Q3, we reported operational sales growth of 6%, ahead of analyst consensus, and increased sequential growth compared to the second quarter. With six strategic focus areas—oncology, immunology, neuroscience, cardiovascular, surgery, and vision—we are leading in areas of higher medical need where innovation can make the greatest difference for patients. Our powerful combination of Innovative Medicine and MedTech expertise strengthens our competitiveness. Twenty-nine of our products and platforms now generate at least $1 billion in annual sales. Our marketed portfolio continues to perform. Our launches are gaining significant traction, and we are advancing our new product pipeline that will sustain our growth into the next decade.

    Frequently Asked Questions About JNJ

    When is Johnson & Johnson's next earnings date?

    Johnson & Johnson's next earnings report is confirmed for Jan 26, 2027, after the close.

    Did JNJ beat earnings estimates last quarter?

    Yes. Johnson & Johnson reported EPS of $2.59 for the quarter ended Sep 30, 2026, above the $2.53 estimate, a 2.37% surprise.

    What EPS do analysts expect from JNJ next quarter?

    The consensus EPS estimate for Johnson & Johnson for the quarter ending Dec 31, 2026 is $2.94 from 18 analysts, with estimates from $2.80 to $3.10.

    How often does JNJ beat earnings estimates?

    Johnson & Johnson beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +2.36%.

    Does JNJ report before or after the market opens?

    Johnson & Johnson is confirmed to report on Jan 26, 2027, after the market closes.